Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis

OBJECTIVE: To assess the frequency of cardiovascular and venous thromboembolic events in clinical studies of baricitinib, an oral, selective JAK1 and JAK2 inhibitor approved in more than 50 countries for the treatment of moderately‐to‐severely active rheumatoid arthritis (RA). METHODS: Data were poo...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Arthritis Rheumatol
Main Authors: Taylor, Peter C., Weinblatt, Michael E., Burmester, Gerd R., Rooney, Terence P., Witt, Sarah, Walls, Chad D., Issa, Maher, Salinas, Claudia A., Saifan, Chadi, Zhang, Xin, Cardoso, Anabela, González‐Gay, Miguel A., Takeuchi, Tsutomu
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2019
Assuntos:
Rheumatoid Arthritis
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6618316/
https://ncbi.nlm.nih.gov/pubmed/30663869
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/art.40841
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados